QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)

Arcellx (ACLX) Stock Forecast, Price & News

$44.15
+0.48 (+1.10%)
(As of 05/31/2023 ET)
Compare
Today's Range
$43.49
$45.66
50-Day Range
$27.49
$46.90
52-Week Range
$11.55
$48.92
Volume
869,345 shs
Average Volume
476,672 shs
Market Capitalization
$2.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.38

Arcellx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
14.1% Upside
$50.38 Price Target
Short Interest
Bearish
22.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Arcellx in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$76.34 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.20) to ($2.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

886th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

145th out of 167 stocks


ACLX stock logo

About Arcellx (NASDAQ:ACLX) Stock

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Stock News Headlines

"The $51 Billion Laser Revolution"
See how a new contract with the Pentagon could spark a 2,476% sales surge for a small laser firm >>>
WARNING TO ALL U.S. INVESTORS
May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update
Arcellx Inc (ACLX) Receives a Buy from Stifel Nicolaus
8-K: Arcellx, Inc.
H.C. Wainwright Keeps Their Buy Rating on Arcellx Inc (ACLX)
See More Headlines
Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Company Calendar

Last Earnings
3/29/2023
Today
5/31/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACLX
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.38
High Stock Price Forecast
$104.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+11.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-188,680,000.00
Pretax Margin
-1,058.80%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.33 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.17 billion
Optionable
Not Optionable
Beta
-0.33

Key Executives

  • Mr. Rami Elghandour (Age 44)
    Chairman, CEO & Pres
    Comp: $803.97k
  • Mr. Neeraj P. Teotia (Age 48)
    Chief Commercial Officer
    Comp: $461.95k
  • Dr. Christopher R. Heery M.D. (Age 43)
    Chief Medical Officer
    Comp: $629.92k
  • Ms. Michelle Lim Gilson (Age 31)
    Chief Financial Officer
  • Mr. Michael Dombeck M.B.A.
    Chief Operating Officer
  • Mr. Narinderjeet Singh M.S. (Age 51)
    Chief Technical Officer
  • Mr. David Tice Ph.D. (Age 52)
    Chief Scientific Officer
  • Ms. Myesha Lacy
    VP of Investor Relations
  • Ms. Maryam Abdul-Kareem J.D.
    M.S., Gen. Counsel
  • Ms. Kate Aiken
    Chief People Officer













ACLX Stock - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings
or view top-rated stocks.

What is Arcellx's stock price forecast for 2023?

11 brokers have issued 12 month target prices for Arcellx's stock. Their ACLX share price forecasts range from $34.00 to $104.00. On average, they anticipate the company's stock price to reach $50.38 in the next year. This suggests a possible upside of 11.3% from the stock's current price.
View analysts price targets for ACLX
or view top-rated stocks among Wall Street analysts.

How have ACLX shares performed in 2023?

Arcellx's stock was trading at $30.98 at the beginning of the year. Since then, ACLX stock has increased by 46.2% and is now trading at $45.28.
View the best growth stocks for 2023 here
.

When is Arcellx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ACLX earnings forecast
.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) announced its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.05.

When did Arcellx IPO?

(ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.

What is Arcellx's stock symbol?

Arcellx trades on the NASDAQ under the ticker symbol "ACLX."

Who are Arcellx's major shareholders?

Arcellx's stock is owned by a number of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.00%), FMR LLC (5.61%), Suvretta Capital Management LLC (5.00%), BlackRock Inc. (4.64%), State Street Corp (3.91%) and Pictet Asset Management SA (2.15%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Scott D Sandell and Sr One Capital Management, Llc.
View institutional ownership trends
.

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcellx's stock price today?

One share of ACLX stock can currently be purchased for approximately $45.28.

How much money does Arcellx make?

Arcellx (NASDAQ:ACLX) has a market capitalization of $2.17 billion. The company earns $-188,680,000.00 in net income (profit) each year or ($4.34) on an earnings per share basis.

How can I contact Arcellx?

The official website for the company is arcellx.com. The company can be reached via phone at 240-327-0603 or via email at ir@arcellx.com.

This page (NASDAQ:ACLX) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -